Matthew Harrison

Q: What is Matthew Harrison's success rate?

Matthew Harrison currently has a success rate of 87.46281178818357.

Q: What is the average return of Matthew Harrison's calls?

Their stock ratings have generated an average return of 19.104830083344147.

Morgan Stanley | Healthcare

Matthew Harrison is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1422 out of 4773 analysts, they have issued 41 stock ratings with a success rate of 87.46% and an average return of 19.10%.

Matthew Harrison has a well-established track record, with 41 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 87.46% and an average return of 19.10%, underscoring their expertise and ability to identify winning opportunities for investors.

#1422

Out of 4773

Total Ratings

+87.46%

Success Rate

+19.10%

Average Return

Recent Ratings Analysis

REGN

Hold

Jul 31, 2026

Target

$758.00

Current

$781.49

Performance

2.47%

Matthew Harrison rated REGN as Equal-Weight on Jul 31, 2026, setting a price target of 758. The Hold stance appears justified, as shares hovered around 781.49 with a 2.47% move.

BIIB

Hold

Jul 30, 2026

Target

$231.00

Current

$217.15

Performance

4.43%

On Jul 30, 2026, BIIB was given a Equal-Weight rating by Matthew Harrison, with a target price of 231. Market indecision, reflected in sideways trading near 217.15, supported the cautious call.

GILD

Buy

Jul 27, 2026

Target

$165.00

Current

$143.72

Performance

10.11%

GILD received a Overweight rating from Matthew Harrison on Jul 27, 2026, aiming for 165. Momentum has favored the Buy call, with shares climbing from 143.72 to 143.72, rewarding those who trusted the recommendation.

R

Buy

Jul 24, 2026

Target

$310.00

Current

$243.30

Performance

-9.11%

On Jul 24, 2026, Matthew Harrison published a Positive outlook on R, with a target of 310. Market action contradicted the Buy thesis, as shares slipped to 243.3.

DNLI

Buy

Jul 23, 2026

Target

$36.00

Current

$21.09

Performance

-9.95%

Matthew Harrison on Jul 23, 2026 assigned DNLI a Overweight rating, with a price target of 36. The call has struggled to gain traction, with shares losing 9.95%.

MRNA

Hold

Jul 08, 2026

Target

$39.00

Current

$143.97

Performance

95.08%

On Jul 08, 2026, Matthew Harrison reaffirmed MRNA with a Equal-Weight rating, targeting 39. Market strength beyond 143.97 went further than the conservative outlook suggested.

ARGX

Buy

Jun 24, 2026

Target

$1180.00

Current

$984.39

Performance

15.47%

ARGX was rated Overweight by Matthew Harrison on Jun 24, 2026, with a price objective of 1180. A bullish response from the market helped close the gap of 195.61 to the target.

LEGN

Buy

May 13, 2026

Target

$48.00

Current

$18.64

Performance

-34.98%

On May 13, 2026, Matthew Harrison initiated coverage on LEGN with a Overweight rating and target of 48. The Buy call has yet to be validated as shares remain 29.36 away from the target.

BMRN

Buy

May 05, 2026

Target

$119.00

Current

$65.68

Performance

23.37%

Matthew Harrison issued a Overweight recommendation for BMRN on May 05, 2026, price target set at 119. Investors following the Buy call captured upside momentum, with shares now at 65.68.

INSM

Buy

Mar 30, 2026

Target

$212.00

Current

$129.41

Performance

-15.59%

On Mar 30, 2026, INSM was evaluated by Matthew Harrison, who gave a Overweight rating and target of 212. Investors saw limited payoff as shares fell short of the 212 target.

PHVS

Buy

Dec 04, 2025

Target

$41.00

Current

$38.02

Performance

37.31%

Matthew Harrison rated PHVS as Overweight on Dec 04, 2025, setting a price target of 41. The call has proven timely, with shares rising 37.31% toward the price target of 41.

ZNTL

Hold

Nov 12, 2025

Target

$4.00

Current

$3.51

Performance

161.94%

On Nov 12, 2025, ZNTL was given a Equal-Weight rating by Matthew Harrison, with a target price of 4. The stock rallied from 3.51 to 3.51 after the Hold rating, surprising to the upside.

IOBT

Buy

Aug 12, 2025

Target

$4.00

Current

$0.01

Performance

-99.06%

IOBT received a Overweight rating from Matthew Harrison on Aug 12, 2025, aiming for 4. The rating hasn’t played out as hoped, with the stock trading 99.06% below expectations.

VRTX

Hold

Aug 05, 2025

Target

$439.00

Current

$515.44

Performance

37.46%

On Aug 05, 2025, Matthew Harrison published a Equal-Weight outlook on VRTX, with a target of 439. The Hold call missed some of the bullish momentum as shares advanced toward 439.

SRPT

Hold

Jul 29, 2025

Target

$20.00

Current

$20.45

Performance

29.19%

Matthew Harrison on Jul 29, 2025 assigned SRPT a Equal-Weight rating, with a price target of 20. Shares outperformed expectations, climbing 29.19% despite the neutral view.

TSVT

Hold

Mar 14, 2025

Target

$5.00

Current

$5.00

Performance

1.01%

On Mar 14, 2025, Matthew Harrison reaffirmed TSVT with a Equal-Weight rating, targeting 5. The neutral call matched muted market action of 1.01%.

TNYA

Buy

Mar 12, 2025

Target

$5.00

Current

$0.64

Performance

6.61%

TNYA was rated Overweight by Matthew Harrison on Mar 12, 2025, with a price objective of 5. A bullish response from the market helped close the gap of 4.36 to the target.

LYV

Buy

Feb 21, 2025

Target

$178.00

Current

$170.15

Performance

13.89%

On Feb 21, 2025, Matthew Harrison initiated coverage on LYV with a Buy rating and target of 178. The stock’s climb of 13.89% since the call highlights the foresight in the rating.

AVNT

Buy

Feb 18, 2025

Target

$56.00

Current

$41.41

Performance

-6.33%

Matthew Harrison issued a Buy recommendation for AVNT on Feb 18, 2025, price target set at 56. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

CMCSA

Buy

Jan 31, 2025

Target

$55.00

Current

$25.20

Performance

-25.13%

On Jan 31, 2025, CMCSA was evaluated by Matthew Harrison, who gave a Buy rating and target of 55. Investors saw limited payoff as shares fell short of the 55 target.

ALEC

Sell

Nov 26, 2024

Target

$3.00

Current

$2.14

Performance

-16.73%

Matthew Harrison rated ALEC as Underweight on Nov 26, 2024, setting a price target of 3. The Sell call didn’t play out, with shares rallying -16.73% to 2.14.

CNTA

Hold

Jun 21, 2024

Target

$11.00

Current

$40.50

Performance

345.05%

On Jun 21, 2024, CNTA was given a Equal-Weight rating by Matthew Harrison, with a target price of 11. The stock rallied from 40.5 to 40.5 after the Hold rating, surprising to the upside.

EDIT

Hold

May 09, 2024

Target

$7.00

Current

$2.70

Performance

-51.44%

EDIT received a Equal-Weight rating from Matthew Harrison on May 09, 2024, aiming for 7. The Hold stance proved prudent, with the market softening by 51.44%.

Frequency Asked Questions

Who is Matthew Harrison?

Matthew Harrison is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Matthew Harrison's success rate?

Matthew Harrison currently has a success rate of +87.46%.

How many ratings has Matthew Harrison issued?

Matthew Harrison has issued 41 stock ratings so far.

What is the average return of Matthew Harrison's calls?

Their stock ratings have generated an average return of +19.10%.

What is Matthew Harrison's ranking?

Matthew Harrison is ranked #1422 out of 4773 analysts.

What types of ratings does Matthew Harrison give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Matthew Harrison?

You can follow Matthew Harrison by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Matthew Harrison?

Their latest rating was a Hold on REGN issued on 2026-07-31.